Qiagen N.V. (QGEN) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
↓
11.81
↓-43% vs avg
5yr avg: 20.69
30Y Low12.8·High89.8
P/FCF
↓
16.80
↓-33% vs avg
5yr avg: 25.14
30Y Low19.8·High193.5
P/B Ratio
↓
2.03
↓-35% vs avg
5yr avg: 3.12
30Y Low1.4·High32.3
ROE
↓
11.6%
↓+8% vs avg
5yr avg: 10.7%
30Y Low-2%·High21%
Debt/EBITDA
↓
2.32
↓-26% vs avg
5yr avg: 3.13
30Y Low0.6·High8.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
QGEN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Qiagen N.V. trades at 18.1x earnings, 59% below its 5-year average of 44.0x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 18%. On a free-cash-flow basis, the stock trades at 16.8x P/FCF, 33% below the 5-year average of 25.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.6B | $9.4B | $10.0B | $10.0B | $11.8B | $13.3B | $12.7B | $7.9B | $8.5B | $7.6B | $7.1B |
| Enterprise Value | $8.4B | $10.2B | $11.0B | $11.0B | $13.1B | $14.5B | $14.1B | $9.0B | $9.5B | $8.7B | $7.7B |
| P/E Ratio → | 18.11 | 22.04 | 120.53 | 27.91 | 25.80 | 23.86 | 175.13 | — | 44.55 | 192.94 | 88.14 |
| P/S Ratio | 3.64 | 4.47 | 5.06 | 5.10 | 5.51 | 5.89 | 6.81 | 5.16 | 5.68 | 5.39 | 5.31 |
| P/B Ratio | 2.03 | 2.47 | 2.80 | 2.63 | 3.41 | 4.28 | 4.55 | 3.11 | 3.24 | 3.01 | 2.72 |
| P/FCF | 16.80 | 20.63 | 19.76 | 33.76 | 20.86 | 30.67 | 67.71 | 140.89 | 40.86 | 47.07 | 28.67 |
| P/OCF | 11.64 | 14.29 | 14.86 | 21.80 | 16.50 | 20.76 | 25.86 | 23.83 | 23.72 | 26.65 | 20.78 |
P/E links to full P/E history page with 30-year chart
QGEN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Qiagen N.V.'s enterprise value stands at 11.8x EBITDA, 43% below its 5-year average of 20.7x. The Healthcare sector median is 14.2x, placing the stock at a 17% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.86 | 5.54 | 5.62 | 6.12 | 6.44 | 7.53 | 5.89 | 6.34 | 6.16 | 5.78 |
| EV / EBITDA | 11.81 | 14.24 | 36.39 | 17.94 | 17.71 | 17.16 | 23.81 | 43.76 | 20.12 | 23.61 | 24.81 |
| EV / EBIT | 16.20 | 19.42 | 66.38 | 22.84 | 22.94 | 21.32 | 27.56 | — | 32.48 | 53.22 | 80.67 |
| EV / FCF | — | 22.43 | 21.63 | 37.21 | 23.15 | 33.53 | 74.88 | 160.57 | 45.60 | 53.78 | 31.24 |
QGEN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Qiagen N.V. earns an operating margin of 24.9%. Operating margins have expanded from 20.9% to 24.9% over the past 3 years, signaling improving operational efficiency. ROE of 11.6% is modest. ROIC of 8.6% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.8% | 61.8% | 48.9% | 62.8% | 64.7% | 64.4% | 65.9% | 65.9% | 66.6% | 65.1% | 63.1% |
| Operating Margin | 24.9% | 24.9% | 4.9% | 20.9% | 24.8% | 28.0% | 20.7% | -1.7% | 17.8% | 10.8% | 7.4% |
| Net Profit Margin | 20.3% | 20.3% | 4.2% | 17.4% | 19.8% | 22.8% | 19.2% | -2.7% | 12.7% | 2.8% | 6.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.6% | 11.6% | 2.3% | 9.4% | 12.9% | 17.4% | 13.5% | -1.6% | 7.4% | 1.6% | 3.1% |
| ROA | 7.1% | 7.1% | 1.4% | 5.5% | 6.8% | 8.5% | 6.5% | -0.8% | 3.5% | 0.9% | 1.9% |
| ROIC | 8.6% | 8.6% | 1.6% | 6.4% | 8.8% | 11.1% | 7.4% | -0.5% | 5.5% | 3.3% | 2.3% |
| ROCE | 9.5% | 9.5% | 1.9% | 7.9% | 10.7% | 12.7% | 8.1% | -0.6% | 5.6% | 3.5% | 2.5% |
QGEN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Qiagen N.V. carries a Debt/EBITDA ratio of 2.3x, which is manageable (28% below the sector average of 3.2x). Net debt stands at $815M ($1.7B total debt minus $839M cash). Interest coverage of 15.7x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.44 | 0.44 | 0.45 | 0.44 | 0.58 | 0.68 | 0.70 | 0.68 | 0.83 | 0.70 | 0.41 |
| Debt / EBITDA | 2.32 | 2.32 | 5.35 | 2.75 | 2.74 | 2.51 | 3.29 | 8.40 | 4.60 | 4.78 | 3.46 |
| Net Debt / Equity | — | 0.22 | 0.27 | 0.27 | 0.37 | 0.40 | 0.48 | 0.43 | 0.38 | 0.43 | 0.24 |
| Net Debt / EBITDA | 1.14 | 1.14 | 3.14 | 1.66 | 1.75 | 1.46 | 2.28 | 5.36 | 2.09 | 2.94 | 2.05 |
| Debt / FCF | — | 1.80 | 1.87 | 3.45 | 2.29 | 2.86 | 7.17 | 19.68 | 4.74 | 6.71 | 2.58 |
| Interest Coverage | 15.74 | 15.74 | 3.76 | 9.05 | 9.78 | 12.49 | 7.16 | -0.05 | 4.35 | 3.30 | 2.46 |
QGEN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Qiagen N.V.'s current ratio of 3.90x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.31x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.99x to 3.90x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.90 | 3.90 | 3.61 | 1.99 | 2.46 | 1.39 | 2.84 | 1.65 | 2.22 | 5.07 | 3.36 |
| Quick Ratio | 3.31 | 3.31 | 3.09 | 1.62 | 2.09 | 1.17 | 2.33 | 1.47 | 2.05 | 4.59 | 2.92 |
| Cash Ratio | 2.15 | 2.15 | 2.12 | 0.98 | 1.46 | 0.70 | 1.25 | 0.79 | 1.46 | 3.20 | 1.73 |
| Asset Turnover | — | 0.33 | 0.35 | 0.32 | 0.34 | 0.37 | 0.32 | 0.29 | 0.26 | 0.28 | 0.31 |
| Inventory Turnover | 2.65 | 2.65 | 3.62 | 1.84 | 2.11 | 2.45 | 2.19 | 3.05 | 3.07 | 3.17 | 3.61 |
| Days Sales Outstanding | — | 70.31 | 84.69 | 95.77 | 73.98 | 76.13 | 94.96 | 115.88 | 96.65 | 99.42 | 89.46 |
QGEN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Qiagen N.V. returns 4.7% to shareholders annually — split between a 0.7% dividend yield and 4.0% buyback yield. The payout ratio of 12.8% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 5.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.7% | 0.6% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | 12.8% | 12.8% | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.5% | 4.5% | 0.8% | 3.6% | 3.9% | 4.2% | 0.6% | — | 2.2% | 0.5% | 1.1% |
| FCF Yield | 6.0% | 4.8% | 5.1% | 3.0% | 4.8% | 3.3% | 1.5% | 0.7% | 2.4% | 2.1% | 3.5% |
| Buyback Yield | 4.0% | 3.3% | 2.9% | 0.2% | 0.2% | 0.8% | 0.5% | 0.9% | 1.2% | 0.8% | 0.0% |
| Total Shareholder Yield | 4.7% | 3.9% | 2.9% | 0.2% | 0.2% | 0.8% | 0.5% | 0.9% | 1.2% | 0.8% | 0.0% |
| Shares Outstanding | — | $208M | $218M | $217M | $223M | $225M | $227M | $220M | $233M | $233M | $230M |
Peer Comparison
Compare QGEN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 QGENYou | $8B | 18.1 | 11.8 | 16.8 | 61.8% | 24.9% | 11.6% | 8.6% | 2.3 |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 NEOG | $2B | -1.9 | 20.8 | — | 47.1% | 1.1% | -41.9% | 0.2% | 6.8 |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 NTRA | $33B | -152.2 | — | 303.7 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $125B | 35.2 | 18.4 | 23.8 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 BIO | $8B | 10.1 | 18.1 | 20.4 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
 TECH | $9B | 126.0 | 44.1 | 35.4 | 64.8% | 8.4% | 3.7% | 3.4% | 2.1 |
 AZTA | $1B | -19.1 | 18.1 | 28.0 | 45.5% | -1.9% | -3.2% | -0.5% | 2.2 |
 PACB | $435M | -0.8 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
QGEN — Frequently Asked Questions
Quick answers to the most common questions about buying QGEN stock.
What is Qiagen N.V.'s P/E ratio?
Qiagen N.V.'s current P/E ratio is 18.1x. The historical average is 62.3x.
What is Qiagen N.V.'s EV/EBITDA?
Qiagen N.V.'s current EV/EBITDA is 11.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 30.3x.
What is Qiagen N.V.'s ROE?
Qiagen N.V.'s return on equity (ROE) is 11.6%. The historical average is 9.9%.
Is QGEN stock overvalued?
Based on historical data, Qiagen N.V. is trading at a P/E of 18.1x. Compare with industry peers and growth rates for a complete picture.
What is Qiagen N.V.'s dividend yield?
Qiagen N.V.'s current dividend yield is 0.71% with a payout ratio of 12.8%.
What are Qiagen N.V.'s profit margins?
Qiagen N.V. has 61.8% gross margin and 24.9% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Qiagen N.V. have?
Qiagen N.V.'s Debt/EBITDA ratio is 2.3x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.